Business / Finance

RSS

Partners congratulate researchers on forming new biotechnology company

The Children's Hospital of Eastern Ontario, The Ottawa Hospital, the University of Ottawa and McMaster University congratulate its researchers on forming Turnstone Biologics Inc., a biotechnology company focused on developing new treatments for cancer that harness the patient's own immune system.

6 May 2015

Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

Transition Therapeutics Inc. today announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company.

6 May 2015

Deben reports on the work of the Microscopy & Histology Core Facility at the University of Aberdeen

Deben reports on the work of the Microscopy & Histology Core Facility at the University of Aberdeen where a newly installed TEM and camera system have enhanced the services provided to users.

5 May 2015

Lucideon and European partners awarded €3.9m to train industry PhD researchers to develop drug-free antibacterial materials

Lucideon, the materials technology company, together with 9 European consortium partners, has been awarded €3.9m (£2.8m) grant by the European Commission to train industry PhD researchers for the development of drug-free antibacterial materials used for medical applications, such as wound care and implants.

From Lucideon 5 May 2015

CMC Biologics to supply bulk drug substance for Emergent BioSolutions' IXINITY

CMC Biologics, Inc., a global CMO dedicated to process development and production of biopharmaceuticals for clinical and commercial use, today announced that it will supply bulk drug substance for Emergent BioSolutions' recently FDA-approved product, IXINITY® [coagulation factor IX (recombinant)].

5 May 2015

Bio-Techne's net sales increase 19% to $114.2 million in third quarter 2015

Bio-Techne Corporation today reported its financial results for the third quarter ended March 31, 2015.

From ProteinSimple 5 May 2015

Karl Storz installs the OR1 NEO® at Spire Harpenden Hopsital

When Spire Harpenden needed to increase its facilities in response to the ever-growing number of patients choosing the hospital for surgery, it approached KARL STORZ for its market-leading OR1 NEO® integrated operating theatre...

From KARL STORZ 1 May 2015

St. Luke's Celebrates Groundbreaking for New Hospital in Monroe County

St. Luke’s University Health Network has broken ground for the new St. Luke’s Hospital-Monroe Campus, adjacent to Wigwam Road and Route 611, in Bartonsville. This will be the first new hospital in Monroe County in 100 years.

30 Apr 2015

Boston Scientific signs two strategic agreements to bring comprehensive solutions to healthcare systems

Boston Scientific announces the signing of two strategic agreements to advance the company's efforts to bring value based solutions aimed at improving outcomes and reducing the cost of cardiovascular care delivery to healthcare systems.

30 Apr 2015

GNC Holdings reports consolidated revenue of $670.2 million for first quarter 2015

GNC Holdings, Inc., a leading global specialty health, wellness and performance retailer, today reported its financial results for the quarter ended March 31, 2015.

30 Apr 2015

HeartWare International's revenue increases 5% to $70.0 million in first quarter 2015

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $70.0 million for the first quarter ended March 31, 2015, a five percent increase compared to $66.5 million in revenue for the same period of 2014.

30 Apr 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014.

30 Apr 2015

Zimmer Holdings reports net sales of $1.13 billion for first quarter 2015

Zimmer Holdings, Inc. today reported financial results for the quarter ended March 31, 2015. The Company reported first quarter net sales of $1.13 billion, a decrease of 2.3% reported and an increase of 4.5% constant currency compared to the first quarter of 2014.

30 Apr 2015

Medicure records net revenue of $3.3 million for first quarter 2015

Medicure Inc., a specialty pharmaceutical company, today reported its results from operations for the first quarter ended March 31, 2015.

30 Apr 2015

Cox Enterprises makes investment in Atlanta-based Rimidi

Cox Enterprises announced today an investment in Atlanta-based Rimidi, a digital health company focused on diabetes and other chronic conditions. This marks a major milestone for the company, paving the way for Rimidi's expansion into additional markets and collaborative opportunities.

29 Apr 2015

Validic raises $12.5 million Series B round led by Kaiser Permanente Ventures

Validic, the healthcare industry's leading digital health platform, announced today that it has secured a $12.5 million Series B round led by Kaiser Permanente Ventures, the corporate venture capital arm of Kaiser Permanente. The funding will continue to fuel Validic's rapid growth.

29 Apr 2015

IDT opens molecular biology R&D facility in Redwood City

Already the world’s leader in custom nucleic acid synthesis, Integrated DNA Technologies (IDT) is capitalizing on its expertise to deliver a broader range of validated molecular biology products. Research and development for these products will now be performed in a newly built facility in Redwood City, California.

From Integrated DNA Technologies 28 Apr 2015

Imprimis has exclusive US commercial rights for patented Hep-Lido-A formulation

Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced it now has the exclusive US commercial rights to the patented compounded alkalinized lidocaine and heparin formulation ("Hep-Lido-A" or "HLA") for the treatment of interstitial cystitis ("IC"), commonly referred to as painful bladder syndrome ("PBS").

28 Apr 2015

Main Street fully exits investment in California Healthcare Medical Billing

Main Street Capital Corporation announced that it recently fully exited its investment in California Healthcare Medical Billing, Inc. CHMB is a provider of outsourced medical billing, revenue cycle management, practice management and electronic health record (EHR) solutions to physicians, clinics, hospitals and health systems throughout the United States.

28 Apr 2015